Absstract of: EP4059425A1

A system comprises electrocardiogram sensing, glucose sensing circuitry, and processing circuitry. The sensing circuitry is configured to sense an electrocardiogram of a patient. The glucose sensing circuitry is configured to sense glucose levels of the patient. The processing circuitry configured to detect atrial fibrillation of the patient during a time unit based on the electrocardiogram of the patient, determine a first metric, wherein the first metric is associated with atrial fibrillation the patient experiences during the time unit, determine a second metric, wherein the second metric is associated with glucose levels of the patient during the time unit, and generate a health metric, wherein the health metric is determined based on the first and second metrics.

Absstract of: WO2021097396A1

A method, system, and computer-readable medium for providing a real-time estimation of laboratory glycosylated hemoglobin (HbAlc) at one or more intervals. The real-time estimation is conferred as a value of estimated, time variable Ale (eAlc) based on daily continuous glucose monitoring (CGM) - derived time in target range (TIR) (CGM-TIR). The eAlc value is adjusted based on a sole laboratory HbAlc value for an interval preceding an interval corresponding to the eAlc value so as to provide an expected value for a laboratory HbAlc value at the same corresponding interval.

Absstract of: WO2022188439A1

A diabetes monitoring and treating apparatus and system based on a mesoporous microneedle. The apparatus comprises: a microneedle counter ionophoresis sensor, which is used for extracting glucose and detecting an electrical signal of the glucose concentration; a control circuit module, which is used for sending a control signal to a microneedle ionophoresis module according to the electrical signal of the glucose concentration; and a microneedle ionophoresis module, which is used for releasing insulin according to the control signal, wherein the control circuit module is connected to the microneedle counter ionophoresis sensor and the microneedle ionophoresis module. By means of the treating apparatus, in the case of minimal invasion, fluctuations in glucose can be accurately tracked and insulin can be correspondingly released, such that the glucose concentration is effectively adjusted. The apparatus can be widely applied to the field of biomedicines.

Absstract of: AU2022218567A1

Disclosed are devices for determining an analyte concentration (e.g., glucose). The devices comprise a sensor configured to generate a signal associated with a concentration of an analyte and a sensing membrane located over the sensor. The sensing membrane comprises a biointerface layer which interfaces with a biological fluid containing the analyte to be measured. The biointerface layer comprises a biointerface polymer, wherein the biointerface polymer comprises polyurethane and/or polyurea segments and one or more zwitterionic repeating units. The biointerface layer increases sensor longevity and decrease sensor inaccuracy by inhibiting accumulation of cells, proteins, and other biological species on the outermost layers of the sensor.

Absstract of: AU2021220861A1

Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.

Absstract of: AU2021219726A1

Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a users insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

Absstract of: US2022288303A1

An article of manufacture for providing a diabetes overlay patch shield is disclosed. The diabetes overlay patch shield includes a vertical supporting wall structure having an outer surface, a top edge and a bottom edge, the vertical supporting wall structure surrounds a cavity configures to match a shape of an on-body device, a set of supporting fingers coupled to the bottom edge of the vertical supporting wall structure radiating outward from the outer surface, the set of supporting fingers having a bottom surface, and adhesive attached to the bottom surface of the set of supporting fingers to hold the diabetes overlay patch shield. An overlay patch sized to cover the entire the diabetes overlay patch shield is attached over the diabetes overlay patch shield once in place.

Absstract of: US2022288300A1

The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).

Absstract of: US2022288313A1

Disclosed herein are techniques related to regulation of insulin on board. In some examples, the techniques may involve obtaining a glucose measurement value generated from a sensing arrangement. The techniques may also involve determining that the glucose measurement value is a valid glucose measurement value. Furthermore, the techniques may involve maintaining a threshold amount of insulin on board (IOB) based on regulating insulin delivery. Maintaining the threshold amount of IOB may be performed responsive to the valid glucose measurement value being less than a threshold glucose value.

Absstract of: US2022288311A1

Exemplary embodiments may modify the cost function parameters based on current and projected mean outcomes in blood glucose level control performance. The exemplary embodiments may modify the weight coefficient R for the insulin cost so that the value of R is not fixed and is not based solely on clinical determined values. Exemplary embodiments may also adjust the cost function to address persistent low-level blood glucose level excursions for users. The exemplary embodiments may reduce the penalty of the insulin cost by the sum of the converted insulin cost of the glucose excursions above target for a period divided by a number of cycles of average insulin action time. The AID system reduces the insulin cost by the lack of insulin in previous cycles.

Absstract of: US2022287652A1

A system and method provides a glucose report for determining glycemic risk based on an ambulatory glucose profile of glucose data over a time period, a glucose control assessment based on median and variability of glucose, and indicators of high glucose variability. Time of day periods are shown at which glucose levels can be seen. A median glucose goal and a low glucose line provide coupled with glucose variability provide a view into effects that raising or lowering the median goal would have. Likelihood of low glucose, median glucose compared to goal, and variability of glucose below median provide probabilities based on glucose data. Patterns can be seen and provide guidance for treatment.

Absstract of: US2022287654A1

A computer-implemented method and a system for analyzing glucose monitoring data indicative of a glucose level, comprising: presenting by a data processing device provided a graphical window on a display device wherein the graphical window comprises a time abscissa axis that defines time units, and a glucose ordinate axis that defines glucose units; receiving a plurality of glucose monitoring values associated with a monitoring time period by the data processing device; segmenting the plurality of glucose monitoring values into a plurality of glucose monitoring traces indicative of the glucose level; defining a reference trace segment; determining the reference trace segment for each of the plurality of glucose monitoring traces; and plotting, for a time window comprising the reference trace segment, the plurality of glucose monitoring traces within the graphical window. Furthermore, a non-transitory computer readable medium is disclosed.

Absstract of: US2022287633A1

Disclosed are processes and techniques implementable by devices and a drug delivery system to maintain optimal drug delivery for a user according to a user's diabetes treatment plan. The disclosed techniques enable a drug delivery device that received an analyte measurement value from an analyte sensor during a prior cycle time to determine a present analyte measurement value has not been received during a present cycle time. A processor of the drug delivery device may, in response to the determination, initiate an action to obtain the present analyte measure value from another device or an estimate of the present analyte measurement value. Based on an outcome of the initiated action, the processor may calculate a dosage of the drug using the present analyte measurement value or information related to the present analyte measurement value. The drug delivery device may also be operable to output the calculated dosage of the drug.

Absstract of: US2022292746A1

An integrated system for the monitoring and treating diabetes is provided, including an integrated receiver/hand-held medicament injection pen, including electronics, for use with a continuous glucose sensor. In some embodiments, the receiver is configured to receive continuous glucose sensor data, to calculate a medicament therapy (e.g., via the integrated system electronics) and to automatically set a bolus dose of the integrated hand-held medicament injection pen, whereby the user can manually inject the bolus dose of medicament into the host. In some embodiments, the integrated receiver and hand-held medicament injection pen are integrally formed, while in other embodiments they are detachably connected and communicated via mutually engaging electrical contacts and/or via wireless communication.

Absstract of: US2022293234A1

The exemplary embodiments may modify a glucose cost component of the cost function of the control loop of an insulin delivery device to compensate for persistent positive low level glucose excursions relative to a target glucose level. The exemplary embodiments may enable use of different glucose cost component functions for different glucose levels of the user. These glucose cost component functions may be employed in piecewise fashion with a different piece being applied for each respective range of glucose level values for the user. The final glucose cost function for calculating the glucose cost component may be a weighted combination of a piecewise glucose cost function and a weighted standard cost function (such as a quadratic function). The weights may reflect the magnitude and/or persistence of glucose excursions relative to a target glucose level.

Absstract of: WO2022192482A1

The exemplary embodiments may modify a glucose cost component of the cost function of the control loop of an insulin delivery device to compensate for persistent positive low level glucose excursions relative to a target glucose level. The exemplary embodiments may enable use of different glucose cost component functions for different glucose levels of the user. These glucose cost component functions may be employed in piecewise fashion with a different piece being applied for each respective range of glucose level values for the user. The final glucose cost function for calculating the glucose cost component may be a weighted combination of a piecewise glucose cost function and a weighted standard cost function (such as a quadratic function). The weights may reflect the magnitude and/or persistence of glucose excursions relative to a target glucose level.

Absstract of: WO2022192106A1

The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).

Absstract of: WO2022192105A1

Exemplary embodiments may modify the cost function parameters based on current and projected mean outcomes in blood glucose level control performance. The exemplary embodiments may modify the weight coefficient R for the insulin cost so that the value of R is not fixed and is not based solely on clinical determined values. Exemplary embodiments may also adjust the cost function to address persistent low-level blood glucose level excursions for users. The exemplary embodiments may reduce the penalty of the insulin cost by the sum of the converted insulin cost of the glucose excursions above target for a period divided by a number of cycles of average insulin action time. The AID system reduces the insulin cost by the lack of insulin in previous cycles.

Absstract of: WO2022192069A1

Disclosed are processes and techniques implementable by devices and a drug delivery system to maintain optimal drug delivery for a user according to a user's diabetes treatment plan. The disclosed techniques enable a drug delivery device that received an analyte measurement value from an analyte sensor during a prior cycle time to determine a present analyte measurement value has not been received during a present cycle time. A processor of the drug delivery device may, in response to the determination, initiate an action to obtain the present analyte measure value from another device or an estimate of the present analyte measurement value. Based on an outcome of the initiated action, the processor may calculate a dosage of the drug using the present analyte measurement value or information related to the present analyte measurement value. The drug delivery device may also be operable to output the calculated dosage of the drug.

Absstract of: EP4056211A2

The present disclosure relates to a liquid medicine injection device including a patch portion to which a sensor portion configured to measure blood glucose is detachable and in which an injection portion configured to inject a liquid medicine into the body of a user is installed, and a stamping portion on which the patch portion is mounted and including a first needle connectable to the sensor portion, wherein the stamping portion transmits power to the patch portion so that the first needle and a second needle, which is connected to the injection portion, are together inserted into the skin of the user, and the sensor portion and the injection portion are installed in a single device so that the convenience of use is improved when the liquid medicine injection device is attached to the skin of the user.

Absstract of: WO2022186444A1

According to the present invention, an applicator for a continuous blood glucose measurement device, the applicator being operated by attaching a body attachment unit to the body of a user, the body attachment unit including a sensor member which is inserted into the body of the user in order to measure the blood glucose, comprises: a main case; a plunger to which the body attachment unit is detachably coupled and which is installed in the main case to be movable from a first position to a second position so that the body attachment unit can be discharged to the outer direction of the main case; a needle which is detachably coupled to the body attachment unit so as to be inserted into the body of the user along with the sensor member; and a needle separating unit which separates the needle from the body of the user by moving the needle in the direction opposite to the discharge direction of the plunger, wherein the needle separating unit includes a locking unit which can be assembled with the plunger in the manner of being engaged with one side of the plunger.

Absstract of: WO2022183740A1

The present invention relates to a method for preparing a differentiated pancreatic beta cell, and the use thereof. Specifically, the method comprises the following steps: (1) performing domesticated cultivation of pluripotent stem cells in a three-dimensional suspension manner; and (2) inducing the domesticated cells to differentiate into pancreatic beta cells. The present invention also relates to a method for preparing an alginate-polylysine-alginate (APA) microencapsulated artificial pancreas islet from the differentiated pancreatic beta cell. The method comprises preparing the microencapsulated artificial pancreas islet by means of using a sodium alginate solution. The present invention further relates to the use of the pancreatic beta cell and the artificial pancreas islet.

Absstract of: WO2022184633A1

A method for measuring a biological parameter, other than glucose concentration, of a biological material is disclosed, as well as a computer readable medium and a sensor system for performing the method. The method comprises irradiating the biological material with optical radiation having a first wavelength between 400 nanometres and 25 micrometres; detecting a first signal from the biological material at the first wavelength; irradiating the biological material with radio-frequency, RF, radiation having a second wavelength between 1 millimetre and 30 centimetres; detecting a second signal from the biological material at the second wavelength; determining the biological parameter of the biological material based on the first signal and the second signal. The sensor system comprises an optical radiation source, an optical radiation detector, an RF radiation source, an RF radiation detector and a processing device.

Absstract of: WO2022184623A1

A method for measuring glucose concentration in a biological material is disclosed, as well as a computer readable medium and a sensor system for performing the method. The method comprises irradiating the biological material with optical radiation having a first wavelength between 400 nanometres and 25 micrometres; detecting a first signal from the biological material at the first wavelength; irradiating the biological material with radio-frequency, RF, radiation having a second wavelength between 1 millimetre and 30 centimetres; detecting a second signal from the biological material at the second wavelength; and determining a concentration of glucose in the biological material based on the first signal and the second signal. The sensor system comprises an optical radiation source, an optical radiation detector, an RF radiation source, an RF radiation detector, and a processing device.

Absstract of: US2022280718A1

A medical device includes an antenna external to a case, package, or encapsulant for the electronic systems of the medical device. In one embodiment, a diabetes infusion pump is enclosed within a metal case, the pump including a processor and a communication module for wireless communications. An antenna is disposed in the delivery tubing of the pump outside the case with an antenna feed interconnecting the external antenna with the internal communication module. In another aspect, a thin film antenna is formed on the outer surface of the case in which a physiological parameter sensor, such as a glucose sensor, is enclosed. Multiple antennas may be used for communications on different frequencies.